THC Eye Drops Did Not Lower Eye Pressure in Glaucoma Patients Despite Working in Animals | Research

The takeaway

Topical THC eye drops effectively lowered eye pressure in laboratory animals but failed to produce the same effect in six glaucoma patients, suggesting THC's eye pressure reduction works through systemic rather than local mechanisms.

Read this if you have heard that cannabis treats glaucoma and want to understand why eye drops have not replaced systemic use.

THC eye drops at 0.05% and 0.1% failed to lower eye pressure in glaucoma patients

What the researchers found

THC was known to lower eye pressure when administered systemically, either by smoking marijuana or taking oral capsules. But systemic THC also lowered blood pressure, an unwanted side effect. Topical eye drops seemed like an obvious solution.

In laboratory animals, topical THC in light mineral oil successfully reduced eye pressure. But when the same approach was tested in six human patients with primary open-angle glaucoma using 0.05% and 0.1% THC solutions, it failed to lower eye pressure.

The researchers offered an important insight: light mineral oil has an affinity for corneal epithelium, making it an optimal vehicle for drugs that work locally within the eye. But if THC's pressure-lowering mechanism is systemic rather than local, this delivery approach would not work. They recommended future research focus on marijuana strains with minimal THC and on alternative local delivery systems for the specific cannabinoid compounds that act directly on the eye.

Why it matters

This study demonstrated a critical pharmacological principle: a drug that works systemically does not necessarily work locally, even at the same target organ. It redirected glaucoma research away from simple THC eye drops toward understanding which specific cannabinoids act locally within the eye.

The numbers in context

Six patients with primary open-angle glaucoma. Two concentrations tested: 0.05% and 0.1% topical THC. Vehicle: light mineral oil. Marijuana strains with less than 0.4% THC recommended for future research.

How the study worked

Randomized, balanced, double-masked protocol testing 0.05% and 0.1% topical THC in light mineral oil on six subjects with primary open-angle glaucoma. Previous animal studies using the same formulation served as comparison.

What this study cannot tell us

Only six patients tested. Only two concentrations used. Only one vehicle (light mineral oil) was tested. The animal-to-human translation failure could reflect species differences, dose differences, or formulation issues rather than a fundamental mechanistic problem.

How to read the evidence

A double-masked, randomized trial but with only six participants. The rigorous design is offset by the very small sample size.

When this study was published

Published in 1981. Drug delivery technology and cannabinoid formulation science have advanced substantially since this study.

The bigger picture

The dream of cannabis-based eye drops for glaucoma has persisted for decades. This early negative finding helped explain why: THC's pressure-lowering effect appears to work through the cardiovascular system rather than directly on the eye. Modern research continues to explore other cannabinoids that may act locally.

Questions still open

Do other cannabinoids lower eye pressure through local rather than systemic mechanisms? Would different vehicles or higher concentrations succeed where mineral oil failed? Has modern formulation science revisited this approach?

Common questions

Do cannabis eye drops work for glaucoma?

In this study, topical THC eye drops did not lower eye pressure in human patients despite working in laboratory animals. The evidence suggests THC reduces eye pressure through systemic circulation, not local action in the eye.

Does smoking cannabis lower eye pressure?

Yes. The review noted that systemic THC, whether smoked or taken orally, does lower eye pressure, but it also lowers blood pressure as an unwanted side effect.

Read the original research

Topical delta 9-tetrahydrocannabinol and aqueous dynamics in glaucoma.

Journal of clinical pharmacology, 21(S1), 467S-471S

View on PubMed ↗

Citation

Merritt, J C; Perry, D D; Russell, D N; Jones, B F. (1981). Topical delta 9-tetrahydrocannabinol and aqueous dynamics in glaucoma.. Journal of clinical pharmacology, 21(S1), 467S-471S.